WO2022201917A1 - 大腸菌を用いた外来タンパク質の製造方法 - Google Patents
大腸菌を用いた外来タンパク質の製造方法 Download PDFInfo
- Publication number
- WO2022201917A1 WO2022201917A1 PCT/JP2022/004680 JP2022004680W WO2022201917A1 WO 2022201917 A1 WO2022201917 A1 WO 2022201917A1 JP 2022004680 W JP2022004680 W JP 2022004680W WO 2022201917 A1 WO2022201917 A1 WO 2022201917A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- coli
- gene
- protein
- strain
- seq
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 299
- 241000588724 Escherichia coli Species 0.000 title claims abstract description 161
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 124
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 23
- 239000012528 membrane Substances 0.000 claims abstract description 38
- 238000012423 maintenance Methods 0.000 claims abstract description 16
- 210000001322 periplasm Anatomy 0.000 claims abstract description 16
- 230000014616 translation Effects 0.000 claims abstract description 8
- 238000012258 culturing Methods 0.000 claims abstract description 7
- 238000000034 method Methods 0.000 claims description 110
- 101150077062 pal gene Proteins 0.000 claims description 44
- 101100203377 Bacillus subtilis (strain 168) slp gene Proteins 0.000 claims description 37
- 101100242529 Drosophila melanogaster Pal2 gene Proteins 0.000 claims description 37
- 101150012565 LRIT1 gene Proteins 0.000 claims description 37
- 101100477497 Mus musculus Shcbp1 gene Proteins 0.000 claims description 37
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 32
- 230000035772 mutation Effects 0.000 claims description 24
- 101150074251 lpp gene Proteins 0.000 claims description 18
- 101100082540 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) pcp gene Proteins 0.000 claims description 15
- 238000012217 deletion Methods 0.000 claims description 13
- 230000037430 deletion Effects 0.000 claims description 13
- 230000004048 modification Effects 0.000 claims description 13
- 238000012986 modification Methods 0.000 claims description 13
- 241000350158 Prioria balsamifera Species 0.000 claims description 12
- 101150115693 ompA gene Proteins 0.000 claims description 10
- 101100295756 Acinetobacter baumannii (strain ATCC 19606 / DSM 30007 / JCM 6841 / CCUG 19606 / CIP 70.34 / NBRC 109757 / NCIMB 12457 / NCTC 12156 / 81) omp38 gene Proteins 0.000 claims description 8
- 101150042295 arfA gene Proteins 0.000 claims description 8
- 101150116543 mrcB gene Proteins 0.000 claims description 8
- 101150087557 omcB gene Proteins 0.000 claims description 8
- 101150077915 oppA gene Proteins 0.000 claims description 8
- 101150094334 slyB gene Proteins 0.000 claims description 8
- 101150061964 tolA gene Proteins 0.000 claims description 8
- 241000180579 Arca Species 0.000 claims description 7
- 101100177265 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) hbpA gene Proteins 0.000 claims description 7
- 101150117498 arcA gene Proteins 0.000 claims description 7
- 101150101009 cyoA gene Proteins 0.000 claims description 7
- 101150029939 dppA gene Proteins 0.000 claims description 7
- 101150066900 ecnB gene Proteins 0.000 claims description 7
- 101150058337 mepS gene Proteins 0.000 claims description 7
- 101150058012 mrcA gene Proteins 0.000 claims description 7
- 101150057035 bamD gene Proteins 0.000 claims description 6
- 101150050698 nlpI gene Proteins 0.000 claims description 6
- 210000004748 cultured cell Anatomy 0.000 claims description 3
- 230000004075 alteration Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 47
- 230000001580 bacterial effect Effects 0.000 abstract description 5
- 239000000284 extract Substances 0.000 abstract description 2
- 230000015572 biosynthetic process Effects 0.000 description 31
- 108020004414 DNA Proteins 0.000 description 28
- 125000003275 alpha amino acid group Chemical group 0.000 description 25
- 239000002773 nucleotide Substances 0.000 description 22
- 125000003729 nucleotide group Chemical group 0.000 description 22
- 230000014509 gene expression Effects 0.000 description 17
- 238000011084 recovery Methods 0.000 description 17
- 239000013604 expression vector Substances 0.000 description 15
- 239000006228 supernatant Substances 0.000 description 15
- 150000001413 amino acids Chemical group 0.000 description 14
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 13
- 239000007983 Tris buffer Substances 0.000 description 13
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 13
- 239000003550 marker Substances 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- 238000011282 treatment Methods 0.000 description 12
- 230000003204 osmotic effect Effects 0.000 description 10
- 230000035939 shock Effects 0.000 description 10
- 210000002808 connective tissue Anatomy 0.000 description 9
- 108010079246 OMPA outer membrane proteins Proteins 0.000 description 8
- 238000003752 polymerase chain reaction Methods 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 7
- 238000011144 upstream manufacturing Methods 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000004098 Tetracycline Substances 0.000 description 6
- 239000012228 culture supernatant Substances 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 229960002180 tetracycline Drugs 0.000 description 6
- 229930101283 tetracycline Natural products 0.000 description 6
- 235000019364 tetracycline Nutrition 0.000 description 6
- 150000003522 tetracyclines Chemical class 0.000 description 6
- 108091026890 Coding region Proteins 0.000 description 5
- 238000012239 gene modification Methods 0.000 description 5
- 230000005017 genetic modification Effects 0.000 description 5
- 235000013617 genetically modified food Nutrition 0.000 description 5
- 239000000819 hypertonic solution Substances 0.000 description 5
- 229940021223 hypertonic solution Drugs 0.000 description 5
- 235000002639 sodium chloride Nutrition 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 4
- 108700006385 OmpF Proteins 0.000 description 4
- 108010013639 Peptidoglycan Proteins 0.000 description 4
- 239000001888 Peptone Substances 0.000 description 4
- 108010080698 Peptones Proteins 0.000 description 4
- 230000003698 anagen phase Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 210000000805 cytoplasm Anatomy 0.000 description 4
- 238000004520 electroporation Methods 0.000 description 4
- 238000003306 harvesting Methods 0.000 description 4
- 230000006801 homologous recombination Effects 0.000 description 4
- 238000002744 homologous recombination Methods 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 235000019319 peptone Nutrition 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 239000013600 plasmid vector Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000006798 recombination Effects 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 230000005945 translocation Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- -1 PhoA Proteins 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 239000001110 calcium chloride Substances 0.000 description 3
- 229910001628 calcium chloride Inorganic materials 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000002738 chelating agent Substances 0.000 description 3
- 229960005091 chloramphenicol Drugs 0.000 description 3
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 229960003964 deoxycholic acid Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000815 hypotonic solution Substances 0.000 description 3
- 239000000411 inducer Substances 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 229930027917 kanamycin Natural products 0.000 description 3
- 229960000318 kanamycin Drugs 0.000 description 3
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 3
- 229930182823 kanamycin A Natural products 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000672609 Escherichia coli BL21 Species 0.000 description 2
- PLUBXMRUUVWRLT-UHFFFAOYSA-N Ethyl methanesulfonate Chemical compound CCOS(C)(=O)=O PLUBXMRUUVWRLT-UHFFFAOYSA-N 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- VZUNGTLZRAYYDE-UHFFFAOYSA-N N-methyl-N'-nitro-N-nitrosoguanidine Chemical compound O=NN(C)C(=N)N[N+]([O-])=O VZUNGTLZRAYYDE-UHFFFAOYSA-N 0.000 description 2
- 101710202686 Penicillin-sensitive transpeptidase Proteins 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 108010022923 Peptidoglycan Glycosyltransferase Proteins 0.000 description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000013599 cloning vector Substances 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 230000004077 genetic alteration Effects 0.000 description 2
- 231100000118 genetic alteration Toxicity 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000010297 mechanical methods and process Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- MBABOKRGFJTBAE-UHFFFAOYSA-N methyl methanesulfonate Chemical compound COS(C)(=O)=O MBABOKRGFJTBAE-UHFFFAOYSA-N 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000006257 total synthesis reaction Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- QAPSNMNOIOSXSQ-YNEHKIRRSA-N 1-[(2r,4s,5r)-4-[tert-butyl(dimethyl)silyl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)C1 QAPSNMNOIOSXSQ-YNEHKIRRSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108010011619 6-Phytase Proteins 0.000 description 1
- 101000992180 Acinetobacter baumannii (strain ATCC 19606 / DSM 30007 / JCM 6841 / CCUG 19606 / CIP 70.34 / NBRC 109757 / NCIMB 12457 / NCTC 12156 / 81) Outer membrane protein Omp38 Proteins 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108010059892 Cellulase Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108010062417 DD-endopeptidase Proteins 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 101710196859 Dipeptide-binding protein Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 101710121765 Endo-1,4-beta-xylanase Proteins 0.000 description 1
- 241001013691 Escherichia coli BW25113 Species 0.000 description 1
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 1
- 101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 description 1
- 108091006020 Fc-tagged proteins Proteins 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010056771 Glucosidases Proteins 0.000 description 1
- 102000004366 Glucosidases Human genes 0.000 description 1
- 108010073324 Glutaminase Proteins 0.000 description 1
- 102000009127 Glutaminase Human genes 0.000 description 1
- 101001086530 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) Outer membrane protein P5 Proteins 0.000 description 1
- 101000878213 Homo sapiens Inactive peptidyl-prolyl cis-trans isomerase FKBP6 Proteins 0.000 description 1
- 102100036984 Inactive peptidyl-prolyl cis-trans isomerase FKBP6 Human genes 0.000 description 1
- 108090000769 Isomerases Proteins 0.000 description 1
- 102000004195 Isomerases Human genes 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 108010054278 Lac Repressors Proteins 0.000 description 1
- 108010059881 Lactase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000012741 Laemmli sample buffer Substances 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 101710112059 Lipoprotein NlpI Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 101710185515 Major outer membrane lipoprotein Lpp Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 108020004485 Nonsense Codon Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101710116435 Outer membrane protein Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 101710195435 Periplasmic oligopeptide-binding protein Proteins 0.000 description 1
- 108010059820 Polygalacturonase Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 101001010097 Shigella phage SfV Bactoprenol-linked glucose translocase Proteins 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000004103 aerobic respiration Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 229940106157 cellulase Drugs 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- AIUDWMLXCFRVDR-UHFFFAOYSA-N dimethyl 2-(3-ethyl-3-methylpentyl)propanedioate Chemical compound CCC(C)(CC)CCC(C(=O)OC)C(=O)OC AIUDWMLXCFRVDR-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 108010093305 exopolygalacturonase Proteins 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 210000003918 fraction a Anatomy 0.000 description 1
- 231100000221 frame shift mutation induction Toxicity 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 229940116108 lactase Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 101150082324 lpp1 gene Proteins 0.000 description 1
- 101150070657 lppA gene Proteins 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 229910017464 nitrogen compound Inorganic materials 0.000 description 1
- 150000002830 nitrogen compounds Chemical class 0.000 description 1
- 230000037434 nonsense mutation Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 101150074527 palA gene Proteins 0.000 description 1
- 229940085127 phytase Drugs 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 229960001134 von willebrand factor Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/185—Escherichia
- C12R2001/19—Escherichia coli
Definitions
- the present invention relates to a method for producing a foreign protein using E. coli.
- Various hosts are used for the production of recombinant proteins using genetic recombination technology.
- animal cells such as CHO (Chinese Hamster Ovary) cells
- microorganisms such as Escherichia coli and yeast.
- Microorganisms have the advantage of being able to produce target proteins in a short time and at a low cost compared to animal cells.
- Escherichia coli is one of the most studied microorganisms, and is frequently used in protein production because it proliferates in a short time and is easy to handle.
- proteins are generally produced intracellularly. ) must be recovered. Especially when cell disruption is involved, it is necessary to purify the target protein from various and large amounts of host-derived substances, and these post-treatment steps greatly affect the production cost of the target protein.
- Contamination of proteins derived from host cells can be reduced by using a method that selectively releases the contents of the periplasm without releasing the contents of the cytoplasm for foreign proteins. Therefore, the process of purifying foreign proteins is easier than the process of purifying them from the cytoplasm.
- the periplasm is an oxidizing environment, it is known that expressing a foreign protein in the periplasm facilitates the formation of intramolecular and intermolecular disulfide bonds and the associated functional expression of the foreign protein. Due to the above circumstances, techniques for expressing foreign proteins in the periplasm are widely used in protein production (eg, Patent Document 1 and Non-Patent Document 1).
- the method of expressing the foreign protein of interest in E. coli and extracting the foreign protein from the periplasm of E. coli is widely used. Different efficiencies are known. Therefore, a technique for efficiently obtaining foreign proteins from E. coli is desired regardless of their molecular weight and the like.
- the present invention provides a method for producing a protein using E. coli, which enables efficient extraction and purification of the foreign protein of interest after localizing it in the E. coli periplasm. for the purpose.
- a method for producing a protein comprising the following steps (a) to (c): (a) introducing a gene encoding a foreign protein of interest into Escherichia coli in which a gene related to maintenance of the outer membrane structure has been modified; (b) a step of culturing the E. coli of (a); and (c) a step of recovering the foreign protein of interest from the periplasmic fraction of the cultured cells.
- the gene associated with maintenance of the outer membrane structure is selected from the group consisting of pal, lpp, ompA, tolA, mepS, nlpI, arcA, bamD, cyoA, dppA, ecnB, mrcA, mrcB, oppA and slyB;
- the method according to (1) wherein at least one of (3) Two or more genes selected from the group consisting of pal, lpp, ompA, tolA, mepS, nlpI, arcA, bamD, cyoA, dppA, ecnB, mrcA, mrcB, oppA and slyB of the E.
- coli are modified.
- the method according to (6), wherein the modification is partial mutation of the signal sequence.
- the method according to (6), wherein the modification is partial mutation of a structural gene.
- a method for producing a protein using Escherichia coli which enables efficient extraction and purification of the protein after localizing the target foreign protein in the Escherichia coli periplasm. It is possible to provide
- the method for producing protein of the present invention is characterized by including the following steps (a) to (c). (a) introducing a gene encoding a foreign protein of interest into Escherichia coli in which a gene related to maintenance of the outer membrane structure has been modified; (b) a step of culturing the E. coli of (a); and (c) a step of recovering the foreign protein of interest from the periplasmic fraction of the cultured cells.
- the method of the present invention is a method capable of efficiently recovering the expressed foreign protein of interest localized in the periplasm of E. coli by providing the above characteristics.
- the term "foreign protein” means a protein that is encoded by a gene that has been integrated from outside the host cell and that is not normally expressed in a non-transformed host cell.
- the Escherichia coli strain used in the method for producing the protein of the present invention is a genetically modified strain, but the Escherichia coli strain that serves as the basis is not particularly limited, and is known.
- E. coli strains can be used.
- the B strain or a strain derived from the B strain, or the K12 strain or a strain derived from the K12 strain can be preferably used.
- the HB101 strain which is a hybrid strain of the B and K12 strains, can be used.
- strains derived from the B strain for example, the BL21 strain and the REL606 strain are known.
- strains derived from the K12 strain W3110 strain, DH10B strain, BW25113 strain, DH5 ⁇ strain, MG1655 strain, JM109 strain, RV308 strain and the like are known.
- the E. coli strain used in the method of the present invention is a genetically modified strain in which one or more genes related to maintenance of outer membrane structure have been modified.
- the term "outer membrane formation-related gene” refers to a gene associated with the maintenance of the outer membrane structure of E. coli. More specifically, the "outer membrane formation-related gene” is a gene of E. coli, that is, a nucleic acid (DNA or RNA, preferably DNA) possessed by E. coli, which is involved in the expression of proteins related to the maintenance of the outer membrane structure of E. coli. point to The adventitia formation-related gene is not particularly limited as long as it is a gene associated with the maintenance of the adventitia structure. , mrcB, oppA and slyB genes.
- the pal, lpp, ompA or tolA gene is more preferred, and the pal or lpp gene is even more preferred. More specifically, a nucleotide sequence represented by any one of SEQ ID NOS: 4 to 32 and 60% or more, 70% or more, 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, A gene having a nucleotide sequence with a sequence identity of 97% or more, 98% or more, or 99% or more is preferred.
- sequence identity of base sequences can be determined using techniques, sequence analysis software, etc. well known to those skilled in the art. Examples include the blastn program of the BLAST algorithm and the fasta program of the FASTA algorithm.
- sequence identity of a base sequence to be evaluated with a base sequence X means that the base sequence X and the base sequence to be evaluated are aligned (aligned), gaps are introduced as necessary, It is a value expressed in % of the frequency at which the same base appears at the same site in the base sequence including the gap portion when the degree of base matching between the two is maximized.
- arcA is a gene for expressing ArcA (Aerobic respiration control).
- An example of the nucleotide sequence of the structural gene encoding ArcA of E. coli is shown in SEQ ID NO:4.
- the signal sequence of arcA is shown in SEQ ID NO:5.
- bamD is a gene for expressing the outer membrane protein BamD.
- An example of the base sequence of the structural gene encoding BamD in E. coli is shown in SEQ ID NO:6.
- the bamD signal sequence is shown in SEQ ID NO:7.
- cyoA is a gene for expressing CyoA, a membrane protein that constitutes the respiratory system.
- An example of the nucleotide sequence of the structural gene encoding E. coli CyoA is shown in SEQ ID NO:8.
- the cyoA signal sequence is shown in SEQ ID NO:9.
- dppA is a gene for expressing DppA, which is a dipeptide binding protein.
- An example of the nucleotide sequence of the structural gene encoding DppA of E. coli is shown in SEQ ID NO:10.
- the signal sequence of dppA is shown in SEQ ID NO:11.
- ecnB is a gene for expressing the toxin lipoprotein EcnB.
- An example of the nucleotide sequence of the structural gene encoding EcnB of E. coli is shown in SEQ ID NO: 12.
- the ecnB signal sequence is shown in SEQ ID NO:13.
- lpp is the gene for expressing the major outer membrane lipoprotein Lpp.
- SEQ ID NO: 14 shows an example of the nucleotide sequence of the structural gene encoding E. coli Lpp.
- the lpp signal sequence is shown in SEQ ID NO:15.
- mepS is a gene for expressing MepS, a peptidoglycan DD-endopeptidase/peptidoglycan LD-peptidase.
- SEQ ID NO: 16 shows an example of the nucleotide sequence of the structural gene encoding E. coli MepS.
- the signal sequence of mepS is shown in SEQ ID NO:17.
- mrcA is a gene for expressing MrcA, a peptidoglycan glycosyltransferase/peptidoglycan DD-transpeptidase.
- An example of the nucleotide sequence of the structural gene encoding MrcA of E. coli is shown in SEQ ID NO: 18.
- the signal sequence of mrcA is shown in SEQ ID NO:19.
- mrcB is a gene for expressing MrcB, a peptidoglycan glycosyltransferase/peptidoglycan DD-transpeptidase.
- An example of the nucleotide sequence of the structural gene encoding MrcB of E. coli is shown in SEQ ID NO:20.
- the signal sequence of mrcB is shown in SEQ ID NO:21.
- nlpI is a gene for expressing lipoprotein NlpI.
- An example of the nucleotide sequence of the structural gene encoding NlpI of E. coli is shown in SEQ ID NO:22.
- the signal sequence of NlpI is shown in SEQ ID NO:23.
- ompA is a gene for expressing the outer membrane protein OmpA.
- An example of the nucleotide sequence of the structural gene encoding E. coli OmpA is shown in SEQ ID NO:24.
- the OmpA signal sequence is shown in SEQ ID NO:25.
- oppA is a gene for expressing the periplasmic oligopeptide-binding protein OppA.
- An example of the nucleotide sequence of the structural gene encoding E. coli OppA is shown in SEQ ID NO:26.
- the signal sequence of oppA is shown in SEQ ID NO:27.
- Pal is a gene for expressing outer membrane lipoprotein Pal.
- SEQ ID NO: 28 shows an example of the nucleotide sequence of the structural gene encoding Pal of Escherichia coli. The signal sequence of pal is shown in SEQ ID NO:29.
- slyB is a gene for expressing SlyB, a peptidyl-prolyl cis-trans isomerase.
- An example of the nucleotide sequence of the structural gene encoding E. coli SlyB is shown in SEQ ID NO:30.
- the signal sequence of slyB is shown in SEQ ID NO:31.
- TolA is a gene for expressing TolA, one of the proteins that make up the Tol/Pal system.
- the Tol/Pal system is a complex composed of multiple proteins present in Gram-negative bacteria, and is reported to be involved in outer membrane invagination during cell division and structural maintenance of the outer membrane.
- SEQ ID NO: 32 shows an example of the nucleotide sequence of the structural gene encoding E. coli TolA.
- modification of a gene refers to a naturally occurring gene (also referred to as “wild-type”) in which the nucleotide sequence is altered. point to The modification referred to here is not particularly limited as long as the base sequence of the original gene is modified in some way, and examples thereof include complete deletion and partial mutation.
- the E. coli genetically modified strain used in the method of the present invention has a genetic modification that alters the expression of one or more outer membrane formation-related genes.
- genetic modification that alters the expression of one or more genes associated with outer membrane formation means genetic modification that significantly changes the activity of the protein encoded by the gene as compared to the parent strain.
- genetic alterations in which the activity of the protein encoded by said gene is attenuated compared to the parent strain are preferred, including genetic alterations in which the activity is completely lost.
- a state in which protein activity is attenuated means a state in which the expression level of mRNA, which is a transcription product of a target gene, or a protein, which is a translation product, is reduced, or a state in which the expression level of a protein, which is a transcription product of a target gene, is reduced.
- a state in which a protein does not function normally as mRNA or protein.
- deficiency of a gene means deletion or damage, preferably deletion.
- the partial mutation includes deletion, insertion, substitution and the like, preferably partial deletion or partial substitution.
- Partial deletion means partially deleting a gene or protein.
- Partial substitution refers to the substitution of a part of the nucleotide sequence of a gene or the amino acid sequence of a protein with another sequence. In the present invention, partial substitution that causes a missense mutation is preferred. .
- the "one or more adventitia formation-related genes" to be modified are also simply referred to as "genes of interest".
- the target gene may be one adventitia formation-related gene or two or more adventitia formation-related genes.
- one adventitia formation-related gene may be modified at a plurality of sites.
- any region such as the N-terminal region, internal region, C-terminal region, etc. may be deleted.
- the sequences before and after the region to be deleted do not have the same reading frame.
- at least a part of the coding region of the amino acid sequence and/or the expression regulatory sequence of the gene of interest for example, the total number of bases of the coding region and/or the expression regulatory sequence, for example, A region consisting of 50% or more, 60% or more, 70% or more, 80% or more, 90% or more, or 95% or more of the number of bases can be deleted. Alternatively, 100% of the region can be deleted (complete deletion).
- the genome DNA may be an Escherichia coli genetically modified strain in which at least the region from the initiation codon to the termination codon of the target gene is deleted.
- the "expression control sequence” is not particularly limited as long as it is a nucleotide sequence that can be involved in the expression of the coding region, and may be a signal sequence and/or SD sequence (eg, 5'-AGGAGGA-3').
- E. coli genetically modified strains of the present invention include modified strains having a complete deletion or partial mutation of the signal sequence and/or SD sequence.
- modification of the target gene in the genomic DNA of E. coli strains include introducing a missense mutation into the amino acid sequence coding region of the gene on the genomic DNA, introducing a stop codon (nonsense mutation), or 1 Examples include introducing a frameshift mutation that adds or deletes up to 2 bases.
- Another example of modification of the target gene in the genomic DNA of an E. coli strain can be achieved by inserting another sequence into the expression regulatory sequence or amino acid sequence coding region of the gene on the genomic DNA.
- the insertion site may be any region of said gene.
- sequences before and after the insertion site do not have the same reading frame.
- Other sequences include, but are not limited to, marker genes. Marker genes include drug resistance markers for drugs such as kanamycin, ampicillin, tetracycline, and chloramphenicol, and auxotrophic markers for nutritional components such as leucine, histidine, lysine, methionine, arginine, tryptophan, and uracil. is not limited to
- the E. coli genetically modified strain can be achieved by, for example, mutation treatment, genetic recombination technology, gene expression suppression treatment using RNAi, gene editing, and the like.
- the mutagenesis treatment includes ultraviolet irradiation, or normal mutagenesis treatments such as N-methyl-N'-nitro-N-nitrosoguanidine (MNNG), ethyl methanesulfonate (EMS), methyl methanesulfonate (MMS), and the like. treatment with a mutagen used in
- a method of preparing an E. coli outer membrane formation-related gene with partial mutation and integrating it into the genome of any E. coli strain can also be suitably used.
- Methods for preparing E. coli outer membrane formation-related genes having partial mutations include methods known to those skilled in the art, for example, overlap PCR method and total synthesis method using appropriate oligonucleotides as primers.
- Known methods can be used as appropriate for the method of incorporating the prepared E. coli outer membrane formation-related gene having partial mutations into host cells. 2000), Proc. Natl. Acad. Sci. Bacteriol., 179, 6228-6237), etc., but the method described in Link et al., which does not integrate foreign genes other than the E. coli genome, is particularly preferable.
- techniques for preparing a recombinant vector of an outer membrane formation-related gene having a partial mutation include a ligation method, In-Fusion (Clontec), a PCR method, a total synthesis method, etc., but are particularly limited to these. not something.
- a ligation method In-Fusion (Clontec)
- a PCR method a total synthesis method, etc.
- a total synthesis method etc.
- periplasmic chaperones such as FkpA, Dsb, and SurA in partial mutant strains.
- Modification of the target gene in the genomic DNA of the E. coli strain can also be achieved by replacing the gene in the genomic DNA of the E. coli strain with a deleted gene or marker gene.
- the deletion-type gene is an inactive gene that has been modified by deleting part or all of the target gene so as not to produce a protein that functions normally.
- deletion-type genes include, for example, a linear DNA containing an arbitrary sequence that does not have the function of the target gene, and the substitution target sites on the genomic DNA (i.e., the above-mentioned A linear DNA comprising sequences upstream and downstream of the target gene (part or all of the target gene), or a linear DNA directly connecting the sequences upstream and downstream of the site to be replaced on the genomic DNA.
- marker genes include, for example, linear DNA containing a sequence of a marker gene, and a site to be replaced on the genomic DNA (that is, part or all of the gene of interest) is located at both ends of the sequence of the marker gene.
- Linear DNA with upstream and downstream sequences is included.
- the marker gene may be removed if necessary after the above replacement.
- FRT flippase recognition target
- E. coli genetically modified strain is a strain in which the pal gene has been modified, E. coli Pal in which the gene (SEQ ID NO: 40) encoding Pal (having the amino acid sequence shown in SEQ ID NO: 33) on the E. coli genome has been mutated. It also includes E. coli in which the gene encoding the signal peptide (SEQ ID NO:42) has been mutated.
- the signal peptide is mutated, other signal peptides such as OmpA, OmpF and Lpp may be used.
- the Pal mutation is preferably partial mutation, particularly partial deletion.
- E. coli containing a partially deleted Pal-encoding gene are E. coli in which the gene (SEQ ID NO: 28) encoding Pal (having the amino acid sequence shown in SEQ ID NO: 33) on the E. coli genome is partially deleted, and Pal E. coli having a partial deletion in the gene (SEQ ID NO: 29) encoding the signal peptide (SEQ ID NO: 34) of E. coli.
- SEQ ID NO: 28 the gene encoding Pal (having the amino acid sequence shown in SEQ ID NO: 33) on the E. coli genome is partially deleted
- Pal E. coli having a partial deletion in the gene (SEQ ID NO: 29) encoding the signal peptide (SEQ ID NO: 34) of E. coli for example, Cascales E. et al. and Lloubes R, (2004), Mol Microbiol. , 51(3), 873-885.
- Pal partial mutants can also be prepared by introducing a gene encoding a partially mutated Pal into a Pal-deficient strain in which the Pal-encoding gene has been deleted, and expressing the partially mutated Pal.
- Escherichia coli in which Pal (SEQ ID NO: 33) is partially mutated, and the partial mutation is more preferably partially deleted.
- the partial mutation of Pal is one or more amino acid sequence portions selected from the signal peptide of Pal, the amino acid sequences of positions 3 to 17, positions 19 to 121, and positions 123 to 152 of SEQ ID NO: 49. Mutations are preferred.
- an E. coli strain having a mutation in Pal for example, an E. coli strain having a gene (SEQ ID NO: 36) encoding Pal (SEQ ID NO: 35) lacking amino acids at positions 3 to 17 on its genome.
- E. coli strain having the encoding gene (SEQ ID NO: 42) on its genome, and a gene (SEQ ID NO: 44) encoding Pal (SEQ ID NO: 43) lacking amino acids at positions 94 to 121.
- E. coli strain having on the genome the E. coli strain having on the genome the gene (SEQ ID NO: 46) encoding Pal (SEQ ID NO: 45) lacking the amino acids at positions 123 to 152, the amino acid at position 126
- an E. coli strain containing the pal gene having the nucleotide sequence shown in any one of SEQ ID NOs: 36, 38, 40, 42, 44, 46, 48 and 50 can be used. preferable.
- Pal having the partial mutation has one or more amino acids substituted, deleted, and/or added in the amino acid sequence shown in any of SEQ ID NOs: 35, 37, 39, 41, 43, 45, 47 and 49. It may be an amino acid sequence obtained by "One or more" is, for example, 1 to 80, preferably 1 to 70, preferably 1 to 60, preferably 1 to 50, preferably 1 to 40, preferably 1 to 30, preferably is 1 to 20, preferably 1 to 15, preferably 1 to 10, preferably 1 to 5, preferably 1 to 4, preferably 1 to 3, preferably 1 to 2, preferably There is one.
- Pal having the partial mutation may have 60% or more sequence identity with the amino acid sequence shown in any of SEQ ID NOs: 36, 38, 40, 42, 44, 46, 48 and 50.
- Said sequence identity may be 70% or more, 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more.
- sequence identity of amino acid sequences can be determined using techniques, sequence analysis software, etc. well known to those skilled in the art.
- the blastp program of the BLAST algorithm and the fasta program of the FASTA algorithm can be used.
- sequence identity of a given amino acid sequence to be evaluated with amino acid sequence X means that the amino acid sequence X and the amino acid sequence to be evaluated are aligned (aligned), gaps are introduced as necessary, It is the value expressed in % of the frequency of appearance of the same amino acid at the same site in the amino acid sequence including the gap portion when the degree of amino acid identity between the two is maximized.
- the E. coli genetically modified strain is a strain in which the lpp gene is modified, a gene encoding Lpp (for example, Lpp having the amino acid sequence of SEQ ID NO: 51) on the E. coli genome (for example, the base sequence of SEQ ID NO: 14 ) mutated, and E. coli mutated in the gene encoding the Lpp signal peptide (eg, the nucleotide sequence of SEQ ID NO: 15).
- Lpp for example, Lpp having the amino acid sequence of SEQ ID NO: 51
- the E. coli genome for example, the base sequence of SEQ ID NO: 14
- E. coli mutated in the gene encoding the Lpp signal peptide eg, the nucleotide sequence of SEQ ID NO: 15
- the signal peptide is mutated, other signal peptides such as OmpA, OmpF and Pal may be used.
- the E. coli genetically modified strain is a strain in which the ompA gene is modified, a gene encoding OmpA (for example, OmpA having the amino acid sequence of SEQ ID NO: 52) on the E. coli genome (for example, the base sequence of SEQ ID NO: 24 ), and E. coli in which the gene encoding the signal peptide of OmpA (eg, the nucleotide sequence of SEQ ID NO: 36) is mutated.
- the signal peptide is mutated, other signal peptides such as Lpp, OmpF, and Pal may be used.
- the E. coli genetically modified strain is a strain in which the tolA gene is modified
- a gene encoding TolA on the E. coli genome for example, TolA having the amino acid sequence shown in SEQ ID NO: 53
- SEQ ID NO: 32 sequence for example, the base of SEQ ID NO: 32 sequence
- step (a) The method of the present invention includes (a) a step of introducing a gene encoding a foreign protein of interest into E. coli in which a gene related to maintenance of outer membrane structure has been modified (hereinafter also referred to as “step (a)”). .
- the method of the present invention includes introducing a gene encoding a foreign protein of interest (foreign protein) into an E. coli genetically modified strain to produce the foreign protein of interest. More specifically, in the method of the present invention, an expression vector containing a gene encoding a foreign protein of interest is introduced into an E. coli genetically modified strain.
- expression vector refers to an artificially constructed nucleic acid molecule that has the function of expressing a gene in an expression cassette integrated into the expression vector in a host cell after transformation.
- the expression vector contains a cloning site containing one or more restriction enzyme recognition sequences, an overlap region for using Clontec's In-Fusion cloning system or the like, a marker gene such as a drug resistance gene, and a self-replicating sequence. etc.
- Expression vectors include, for example, plasmid vectors and artificial chromosomes. Plasmid vectors are preferably used because they facilitate vector preparation and transformation of E. coli strains. Examples of plasmids include known expression vectors such as pBR322, pBR325, pUC118, pUC119, pUC18, pUC19 and pBluescript, but are not particularly limited thereto.
- An "expression cassette” is composed of a promoter and a gene encoding a foreign protein, and may contain a terminator. Promoters to be used include promoters known to those skilled in the art, such as lac promoter, tac promoter, ara promoter, tet promoter and T7 promoter, but are not particularly limited thereto.
- the method of the present invention requires that the foreign protein of interest be transferred from the cytoplasm of E. coli to the periplasmic space. Therefore, it is required that a periplasmic localization signal sequence is added to the 5' end of the gene encoding the foreign protein.
- Periplasmic translocation signals that function in E. coli include, but are not limited to, PelB, OmpA, PhoA, OmpF, STII, and the like.
- a periplasmic translocation signal is required for translocation to the periplasmic space, and the addition of a periplasmic translocation signal is not required for a foreign protein.
- the base sequence of the gene encoding the foreign protein (foreign gene) to be incorporated into the expression vector is 200 to 4,500 bp, particularly 500 bp, due to the stability of the expression vector and high efficiency of introduction into the host. It is preferable to set the length to about 2,000 bp.
- foreign proteins produced by the method of the present invention include enzymes derived from microorganisms and proteins derived from multicellular organisms such as animals and plants.
- examples include phytase, protein A, protein G, protein L, amylase, glucosidase, cellulase, lipase, protease, glutaminase, peptidase, nuclease, oxidase, lactase, xylanase, trypsin, pectinase, isomerase, and fluorescent proteins. It is not limited to these. Biopharmaceutical proteins are particularly preferred.
- biopharmaceutical proteins include partial antibodies such as VHH, scFv, and Fab, cytokines, growth factors, protein kinases, protein hormones, Fc fusion proteins, and human serum albumin (HSA) fusion proteins.
- amino acids that make up the foreign protein may be natural or non-natural, or may be modified.
- amino acid sequence of the protein may be artificially modified or designed de-novo.
- the drug resistance marker gene of the plasmid vector in the present invention is not particularly limited in the E. coli strain provided by the present invention. Specific examples include kanamycin-resistant genes, ampicillin-resistant genes, tetracycline-resistant genes, chloramphenicol-resistant genes, etc., which can be selected by resistance in media containing kanamycin, ampicillin, tetracycline, and chloramphenicol, respectively. is possible.
- the expression vector is introduced into the genetically modified E. coli strain.
- Techniques for introducing an expression vector into an E. coli strain are not particularly limited, and for example, gene transfer methods such as electroporation, calcium chloride, competent cell and protoplast methods can be used.
- Step (b) The method of the present invention includes a step of culturing the E. coli genetically modified strain introduced with the gene encoding the foreign protein obtained in step (a) (hereinafter also referred to as “step (b)”).
- the above-mentioned E. coli genetically modified strain can be cultured in an appropriate medium.
- the culture method may be batch culture, fed-batch culture, or continuous culture.
- the medium may be either a synthetic medium or a natural medium, as long as it contains nutrients such as carbon sources, nitrogen sources, inorganic salts, vitamins, etc. necessary for growth of the genetically modified strain of E. coli.
- the carbon source may be any carbon source that can be assimilated by the genetically modified strain of Escherichia coli, and includes sugars such as glucose and fructose, alcohols such as ethanol and glycerol, and organic acids such as acetic acid. be able to.
- Nitrogen sources include ammonia, ammonium salts such as ammonium sulfate, nitrogen compounds such as amines, and natural nitrogen sources such as peptone.
- inorganic salts include potassium phosphate, magnesium sulfate, sodium chloride, ferrous sulfate, and potassium carbonate.
- vitamins examples include biotin and thiamine.
- substances required for the growth of the E. coli genetically modified strain for example, required amino acids in the case of an amino acid-requiring strain) can be added.
- a medium containing peptone, yeast extract and sodium chloride is preferably used.
- the peptone is preferably soy peptone.
- a preferred example of a medium containing peptone, yeast extract and sodium chloride is 2xYT medium.
- culture conditions are not particularly limited, but preferred examples include shaking culture and stirring culture.
- the culture temperature is 20-50°C, preferably 20-42°C, more preferably 25-33°C.
- the culture time is 3 hours to 5 days, preferably 5 hours to 3 days.
- nutrients or inducers can be supplied to the medium by shot or fed-batch as needed.
- the inducer is appropriately selected depending on the promoter used. For example, direct induction of the lac promoter or tac promoter, or indirect induction of the T7 promoter by expressing T7 RNA polymerase with the lac promoter, lactose, isopropyl- ⁇ -Thiogalactopyranoside (IPTG) and the like are used.
- IPTG is used as an inducer
- protein expression can be induced by adding IPTG to a final concentration of 0.1 to 2.0 mM, more preferably 0.2 to 1.0 mM.
- timing of inducing the expression of the foreign protein is not particularly limited as long as the foreign protein is expressed and secreted into the culture supernatant, but is preferably early logarithmic growth phase, mid-logarithmic growth phase or late logarithmic growth phase. , particularly preferably in the late logarithmic growth phase.
- Step (c) The method of the present invention includes a step of recovering the foreign protein of interest from the periplasmic fraction of the E. coli genetically modified strain cultured in step (b) (hereinafter also referred to as “step (c)”).
- Bacteria can be recovered from the culture solution by any known technique such as centrifugation. At that time, in order to further improve the yield of the target protein, the culture supernatant may be collected and the target protein may be purified separately from the cells.
- a target protein is recovered from the recovered cells.
- it is necessary to extract the protein from the periplasmic fraction of the bacterial cells without performing a bacterial cell disruption treatment in order to suppress the contamination of the protein in the cytoplasm.
- Any known technique can be used for extracting protein from the periplasmic fraction in step (c).
- Known techniques for extracting proteins from the periplasmic fraction of Escherichia coli include, for example, osmotic shock method, chelating agent treatment, treatment with cell wall-degrading enzymes such as lysozyme, treatment with weak chaotropic substances (e.g., arginine) (e.g., patent documents 1), heat treatment, low-concentration surfactant treatment, and freeze-thaw.
- osmotic shock method chelating agent treatment
- treatment with cell wall-degrading enzymes such as lysozyme
- treatment with weak chaotropic substances e.g., arginine
- heat treatment low-concentration surfactant treatment
- freeze-thaw freeze-thaw.
- chemical methods particularly the cold osmotic shock method using osmotic shock, are preferred over mechanical methods such as sonication and high-pressure homogenizers. , the use of chelating agents, and the use of low concentrations of surfactants. It is known that the yield of target protein by such chemical methods is generally lower than that by mechanical methods.
- the method of the present invention uses a genetically modified strain of Escherichia coli, making it possible to obtain the desired protein at a high yield even by a chemical method.
- the cold osmotic shock method is the most common method used to extract the periplasmic fraction, and for example, the following methods can be used. After suspending the cells in a sucrose hypertonic solution prepared using an EDTA/Tris buffer, the cells are collected and suspended in ice-cold water. The cells are harvested again and the supernatant is obtained as the periplasmic fraction. Here, before suspending the cells in the hypertonic solution, the cells may be washed with a Tris buffer. In addition, the suspension and harvesting of the cells in the hypertonic solution may be carried out in multiple cycles.
- the following method can be used as a method using a chelating agent.
- Cells are suspended in a weakly basic Tris/EDTA buffer containing a relatively high concentration of EDTA and incubated at room temperature for 15 minutes to 6 hours. Harvest again to obtain the supernatant as the periplasmic fraction. The suspension and harvesting of the cells in the Tris/EDTA buffer may be repeated.
- Tris/EDTA method the above method is also referred to as "Tris/EDTA method”.
- a method using a low-concentration surfactant for example, a method using bile salts such as sodium cholate and sodium deoxycholate, which are less likely to cause protein denaturation, can be used. Specifically, for example, the following method can be used.
- the cells are suspended in a sodium deoxycholate solution of about 0.15% by weight, shaken at room temperature for about 30 minutes to 7 hours, collected, and the supernatant is obtained as a periplasmic fraction. Multiple cycles of suspension and harvesting of the cells in the sodium deoxycholate solution may be performed.
- the periplasmic fraction when using a normal E. coli strain, may not contain a sufficient amount of protein depending on the type of target protein.
- the method of the present invention has the advantage that the periplasmic fraction can contain a larger amount of the target protein.
- a target protein can be purified from the periplasmic fraction. Any known technique can be used as a protein purification technique. For example, ammonium sulfate precipitation, gel filtration, ion exchange chromatography, affinity chromatography and the like can be used. Since the method of the present invention does not involve disrupting cells, it is possible to efficiently purify the target protein in a state where there is little contamination with proteins other than the target.
- the protein may be purified from the culture supernatant separately from or mixed with the periplasmic fraction. By recovering proteins also from the culture supernatant, it becomes possible to further increase the protein yield.
- the method for producing host E. coli for producing the protein of the present invention includes the following steps (i) and (ii). It is characterized by (i) a step of modifying a gene associated with maintenance of the outer membrane structure of E. coli; and (ii) a step of introducing a gene encoding a foreign protein of interest into the gene-modified E. coli obtained in (i) .
- E. coli produced by the method for producing host E. coli of the present invention expresses the foreign protein of interest by the introduced gene. At that time, the foreign protein of interest is preferably accumulated in the periplasm of the E. coli.
- the method for producing the host E. coli of the present invention includes a step of modifying an E. coli outer membrane formation-related gene (hereinafter also referred to as “step (i)”).
- the E. coli strain used in the method for producing the host E. coli of the present invention is as described in the section “1-1 E. coli strain” in “1 Method for producing protein” above.
- the adventitia formation-associated gene to be modified is as described in the above section "1-2 Artsitia formation-associated gene”.
- specific methods, conditions, and the like for modifying the E. coli outer membrane formation-related gene are as described in the above section “1-3 E. coli strains with modified outer membrane formation-related gene”.
- step (ii) The method for producing host E. coli of the present invention includes a step of introducing a gene encoding a foreign protein of interest into the E. coli genetically modified strain obtained in step (i) (hereinafter also referred to as “step (ii)”). .
- step (ii) the expression vector used for gene introduction, the method of introduction, etc. are as described in the above “1-4 Gene introduction step (step (a))”.
- the amino acid number described in the present invention is the number in the full-length protein including the signal sequence.
- Genetic recombination techniques used in the present invention such as polymerase chain reaction (PCR), gene synthesis, DNA isolation and purification, restriction enzyme treatment, modified DNA cloning, transformation, etc., are known to those skilled in the art. The following examples were carried out according to the procedures described in the reagent and instrument manufacturer's accompanying manuals, unless otherwise specified.
- the plasmid vector used for transformation is the E. coli E. coli constructed vector. It was prepared by introducing into E. coli DH5 ⁇ competent cells (Takara Bio Inc.) and culturing and amplifying the resulting transformant. Plasmids were extracted from plasmid-carrying strains using FastGene Plasmid Mini Kit (Nippon Genetics). The cloning vector used was a modified pTH18cs (National Institute of Genetics: NIG) having a tetracycline resistance gene as a marker. An expression vector having a lac repressor gene was used to express the target protein.
- NIG National Institute of Genetics
- Example 1 Preparation of genetically modified Escherichia coli strains associated with outer membrane formation E. coli strains lacking pal, partially lacking pal, and point mutants of lpp were prepared according to Link A. et al. J. (J. Bacteriol., 1997 179, 6228-6237). To completely delete the pal gene, a DNA fragment (SEQ ID NO: 1) having EcoRI and SalI cleavage sites at both ends and homologous arms of about 500 bp each upstream and downstream outside the pal gene was amplified by PCR. The DNA fragment and cloning vector prepared above were cleaved with restriction enzymes EcoRI and SalI, and each cleaved DNA fragment was used for ligation.
- the plasmid (p ⁇ pal) thus prepared was introduced into Escherichia coli BL21 strain by the calcium chloride method, and a p ⁇ pal-carrying strain was selected using a medium containing tetracycline. See Link A. above. J. It was confirmed by these methods that the target gene had been deleted by homologous recombination, and the obtained modified strain was designated as the ⁇ pal strain.
- ppal1 and plpp1 were each introduced into Escherichia coli BL21 strain, and modified strains were selected using a medium containing tetracycline. Modification of the target gene by homologous recombination was confirmed, and the resulting modified strains were designated as pal1 strain and lpp1 strain, respectively.
- Example 2 Measurement of recovery efficiency of target protein from outer membrane formation-associated genetically modified E. coli strain was carried out to investigate the recovery efficiency of In this example, various Escherichia coli were made to produce anti-von Willebrand factor (vWF) VHH antibodies as target proteins, and their recovery efficiency was investigated.
- E. coli into which an expression vector containing a gene (SEQ ID NO: 54) encoding an anti-vWF VHH antibody was introduced by electroporation was cultured in 1 mL of semi-synthetic medium. The recovery efficiency of the target protein recovered from the periplasmic fraction of each E. coli strain was calculated, assuming that the sum total of the anti-vWF nanobody (target protein) contained in the soluble fraction of the cells was 100% recovery. Each fraction was prepared using the following two techniques respectively.
- the supernatant was collected as hypertonic fraction 2 and the cells were suspended in 250 ⁇ L of ice-cold hypotonic solution (1 mM MgCl 2 ). The suspension was centrifuged at 12,000 ⁇ g for 5 minutes and the supernatant was collected as hypotonic fraction 1. Cells were suspended in 250 ⁇ L of hypotonic solution, centrifuged at 12,000 ⁇ g for 5 minutes, and the supernatant was collected as hypotonic solution fraction 2. Cells were suspended in 250 ⁇ L of PBS, crushed twice with an ultrasonicator (UH-50: SMT) for 30 seconds, centrifuged at 12,000 ⁇ g for 5 minutes, and the supernatant was used as crushed fraction 1. Recovered. The cells were suspended in 250 ⁇ L of PBS, washed, centrifuged at 12,000 ⁇ g for 5 minutes, and the supernatant was collected as the crushed fraction 2.
- UH-50: SMT ultrasonicator
- Tris/EDTA method As in (1), 250 ⁇ L of the culture medium was centrifuged at 6,400 xg for 10 minutes to separate the supernatant and cells. Cells were suspended in 250 ⁇ L of Tris/EDTA buffer (100 mM Tris/HCl, 10 mM EDTA pH 7.4), allowed to stand at room temperature for 90 minutes, centrifuged at 12,000 ⁇ g for 5 minutes, and the supernatant was centrifuged at 12,000 ⁇ g for 5 minutes. Collected as /E fraction 1. Cells were washed by resuspending the cells in 250 ⁇ L of Tris/EDTA buffer and centrifuging at 12,000 ⁇ g for 5 minutes. The supernatant was collected as T/E fraction 2.
- Tris/EDTA buffer 100 mM Tris/HCl, 10 mM EDTA pH 7.4
- Cells were suspended in 250 ⁇ L of PBS, crushed twice with an ultrasonicator (UH-50: SMT) for 30 seconds, centrifuged at 12,000 ⁇ g for 5 minutes, and the supernatant was used as crushed fraction 1. Recovered. The cells were suspended in 250 ⁇ L of PBS, washed, centrifuged at 12,000 ⁇ g for 5 minutes, and the supernatant was collected as the crushed fraction 2.
- UH-50: SMT ultrasonicator
- a part of the target protein was observed to be secreted in the culture supernatant in all strains (data not shown). It was found that the recovery amount of the target protein can be further improved by further recovering the target protein in the culture supernatant.
- Example 3 Measurement of target protein recovery efficiency from outer membrane formation-related genetically modified E. coli strains using Keio collection This experiment was carried out to examine the recovery efficiency of the target protein from the genetically modified E. coli strain.
- the ompA, tolA, mepS, nlpI, arcA, cyoA, dppA, ecnB, mrcA, mrcB, oppA, and slyB-deficient strains of the Keio collection which is a mutant strain of Escherichia coli BW25113, were added with an anti-vWF nanobody as the target protein. was produced and its recovery efficiency was examined.
- An expression vector containing a gene (SEQ ID NO: 54) encoding an anti-vWF nanobody was introduced into each mutant by electroporation, and cultured in 0.8 mL of semi-synthetic medium.
- the recovery efficiency of the target protein recovered from the periplasmic fraction was calculated by setting the total recovery rate of the anti-vWF nanobody (target protein) contained in the soluble fraction of the cells to 100%.
- Each fraction was prepared by the cold osmotic shock method under the same conditions as in Example 2.
- the anti-vWF nanobody in each fraction was subjected to Western blotting analysis under the same conditions as in Example 2.
- the recovery rate of the anti-vWF nanobody in each fraction was calculated from the band intensity.
- the sum of the hypertonic fractions 1 and 2 and the hypotonic fractions 1 and 2 was taken as the recovered amount.
- a comparison of the wild-type strain and the genetically modified E. coli strain related to outer membrane formation showed that any It was confirmed that the recovery rate by the cold osmotic shock method was also improved in E. coli with genetically modified outer membrane formation-related genes.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
(1)下記の(a)~(c)の工程を含む、タンパク質の製造方法:
(a)外膜構造の維持に関連する遺伝子が改変された大腸菌に目的の外来タンパク質をコードする遺伝子を導入する工程、
(b)(a)の大腸菌を培養する工程、及び
(c)培養後の菌体のペリプラズム画分より目的の外来タンパク質を回収する工程。
(2)前記外膜構造の維持に関連する遺伝子が、pal、lpp、ompA、tolA、mepS、nlpI、arcA、bamD、cyoA、dppA、ecnB、mrcA、mrcB、oppA及びslyBからなる群から選択される少なくとも1つである、(1)に記載の方法。
(3)前記大腸菌の、pal、lpp、ompA、tolA、mepS、nlpI、arcA、bamD、cyoA、dppA、ecnB、mrcA、mrcB、oppA及びslyBからなる群から選択される2つ以上の遺伝子が改変されている、(1)又は(2)に記載の方法。
(4)前記大腸菌の、pal、lpp、ompA及びtolAからなる群から選択される少なくとも1つの遺伝子が改変されている、(1)又は(2)に記載の方法。
(5)前記改変が完全欠損である、(1)~(4)のいずれかに記載の方法。
(6)前記改変が部分変異である、(1)~(4)のいずれかに記載の方法。
(7)前記改変がシグナル配列の部分変異である(6)に記載の方法。
(8)前記改変が構造遺伝子の部分変異である(6)に記載の方法。
(9)前記大腸菌が、B株由来またはK12株由来である(1)~(8)のいずれかに記載の方法。
(10)タンパク質を製造するための宿主大腸菌の作製方法であって、下記の(i)及び(ii)の工程を含む、方法:
(i)大腸菌の外膜構造の維持に関連する遺伝子に改変を加える工程;及び
(ii)(i)で得られた遺伝子が改変された大腸菌に、目的の外来タンパク質をコードする遺伝子を導入する工程。
(11)前記大腸菌が目的の外来タンパク質を発現し、前記目的の外来タンパク質が前記大腸菌のペリプラズムに蓄積される、(10)に記載の方法。
本明細書は本願の優先権の基礎となる日本国特許出願番号2021-046808号の開示内容を包含する。
本発明のタンパク質の製造方法は、下記の(a)~(c)の工程を含むことを特徴とする。
(a)外膜構造の維持に関連する遺伝子が改変された大腸菌に目的の外来タンパク質をコードする遺伝子を導入する工程、
(b)(a)の大腸菌を培養する工程、及び
(c)培養後の菌体のペリプラズム画分より目的の外来タンパク質を回収する工程。
本発明の方法は、上記の特徴を備えることにより、大腸菌のペリプラズムに局在する発現した目的の外来タンパク質を、効率よく回収することが可能な方法である。
本発明のタンパク質の製造方法(以下、「本発明の方法」とも称する)に使用する大腸菌は、遺伝子改変株であるが、その基となる大腸菌株は特に限定されず、公知の大腸菌株をいずれも使用できる。特に、B株若しくはB株から派生した株、又は、K12株若しくはK12株から派生した株を好適に使用できる。あるいは、B株とK12株とのハイブリッド株であるHB101株を使用できる。B株から派生した株としては、例えば、BL21株、REL606株が知られる。また、K12株から派生した株としては、W3110株、DH10B株、BW25113株、DH5α株、MG1655株、JM109株、RV308株等が知られる。
本発明の方法に使用する大腸菌株は、1以上の外膜構造の維持に関連する遺伝子が改変された遺伝子改変株である。
本明細書において、遺伝子の「改変」とは、天然に存在する遺伝子(「野生型」とも称する)に対して、塩基配列の変更が加わることを指す。ここでいう改変は、元の遺伝子の塩基配列に対して何らかの変更が加えられていれば、特に制限されないが、例えば、完全欠損又は部分変異が挙げられる。
本発明の方法は、(a)外膜構造の維持に関連する遺伝子が改変された大腸菌に目的の外来タンパク質をコードする遺伝子を導入する工程(以下、「工程(a)」とも称する)を含む。
本発明の方法は、大腸菌遺伝子改変株に目的の外来タンパク質(外来タンパク質)をコードする遺伝子を導入し、目的の外来タンパク質を生成させることを含む。より具体的には、本発明の方法において、大腸菌遺伝子改変株には、目的の外来タンパク質をコードする遺伝子を含む発現ベクターが導入される。
本発明の方法において、遺伝子改変大腸菌株に前記発現ベクターが導入される。発現ベクターを大腸菌株に導入する手法は、特に制限されないが、例えば、エレクトロポレーション法、塩化カルシウム法、コンピテントセル法、プロトプラスト法等の遺伝子導入法により行うことができる。
本発明の方法は、前記工程(a)で得られた外来タンパク質をコードする遺伝子を導入した大腸菌遺伝子改変株を培養する工程(以下「工程(b)」とも称する)を含む。
本発明の方法は、工程(b)で培養された大腸菌遺伝子改変株の菌体のペリプラズム画分より、目的の外来タンパク質を回収する工程(以下、「工程(c)」とも称する)を含む。
培養液からの菌体の回収は、遠心分離等の公知の手法をいずれも使用できる。その際、目的タンパク質の収率をさらに向上させるため、培養上清を回収し、菌体とは別に目的タンパク質を精製してもよい。
回収された菌体から、目的タンパク質を回収する。目的タンパク質の回収に際しては、細胞質内のタンパク質の混入を抑制するため、菌体破砕処理を行わず、菌体のペリプラズム画分からタンパク質を抽出することを要する。工程(c)においてペリプラズム画分からタンパク質を抽出する手法は、公知の手法をいずれも使用できる。
前記ペリプラズム画分から、目的タンパク質を精製することができる。タンパク質の精製手法としては、公知の手法をいずれも使用可能である。例えば、硫酸アンモニウム沈殿、ゲルろ過、イオン交換クロマトグラフィー、アフィニティークロマトグラフィー等を使用することができる。本発明の方法は、細胞の破砕を伴わないことにより、目的以外のタンパク質の混入が少ない状態から、目的タンパク質を効率よく精製することが可能である。
本発明のタンパク質を製造するための宿主大腸菌の作製方法(以下、「本発明の宿主大腸菌の作製方法」とも称する)は、下記の(i)及び(ii)の工程を含むことを特徴とする。
(i)大腸菌の外膜構造の維持に関連する遺伝子を改変させる工程;及び
(ii)(i)で得られた遺伝子が改変された大腸菌に、目的の外来タンパク質をコードする遺伝子を導入する工程。
本発明の宿主大腸菌の作製方法は、大腸菌の外膜形成関連遺伝子を改変させる工程(以下、「工程(i)」とも称する)を含む。本発明の宿主大腸菌の作製方法において、使用する大腸菌株は、上記「1 タンパク質の製造方法」の「1-1 大腸菌株」の項に記載した通りである。また、改変に対象となる外膜形成関連遺伝子は、上記「1-2 外膜形成関連遺伝子」の項に記載した通りである。さらに、大腸菌の外膜形成関連遺伝子を改変させる具体的な手法、条件等は、上記「1-3 外膜形成関連遺伝子が改変された大腸菌株」の項に記載した通りである。
本発明の宿主大腸菌の作製方法は、工程(i)で得られた大腸菌遺伝子改変株に、目的の外来タンパク質をコードする遺伝子を導入する工程(以下、「工程(ii)」とも称する)を含む。工程(ii)において、遺伝子導入に使用する発現ベクター、導入手法等は、上記「1-4 遺伝子導入工程(工程(a))」に記載した通りである。
大腸菌のpal全欠損、部分欠損株およびlppの点変異株をLink A.J.他(J.Bacteriol.,1997年 179,6228-6237)の方法を参考にして調製した。pal遺伝子を全欠損させるために、PCR法により、両端にEcoRIおよびSalI切断部分を有し、pal遺伝子外の上流・下流それぞれ約500bpのホモロジーアームを有するDNA断片(配列番号1)を増幅した。上記で調製したDNA断片およびクローニングベクターを、制限酵素EcoRIとSalIによって切断し、各切断されたDNA断片を用いてライゲーションを行った。このように調製したプラスミド(pΔpal)を大腸菌BL21株に塩化カルシウム法で導入し、テトラサイクリンを含む培地を用いてpΔpal保持株を選択した。上記Link A.J.らの方法で、相同組換えにより目的の遺伝子が欠損されたことを確認し、得られた改変株をΔpal株とした。
本実施例は、野生株および実施例1で調製した3種の外膜形成関連遺伝子改変大腸菌株からの目的タンパク質の回収効率を調べるために実施した。本実施例では、各種大腸菌に目的タンパク質として抗フォン・ヴィレブランド因子(vWF)VHH抗体を産生させ、その回収効率を調べた。抗vWF VHH抗体をコードする遺伝子(配列番号54)を含む発現用ベクターをエレクトロポレーション法によって導入した大腸菌を1mLの半合成培地で培養した。菌体の可溶性画分に含まれる抗vWFナノボディ(目的タンパク質)の総和を回収率100%として、各大腸菌株におけるペリプラズム画分から回収された目的タンパク質の回収効率を算出した。各画分は、以下の2つの手法をそれぞれ用いて調製した。
250μLの培養液を6,400×gで10分間遠心分離し上清と細胞に分けた。細胞を250μLの高張液(100mM Tris/HCl、500mM スクロース、0.5mM EDTA pH8.0)に懸濁し、室温で10分間静置した後、12,000×gで5分間遠心分離し、上清を高張液画分1として回収した。細胞を、250μLの高張液に再度懸濁して細胞を洗浄し、12,000×gで5分間遠心分離した。上清を高張液画分2として回収し、細胞を250μLの氷冷した低張液(1mM MgCl2)に懸濁した。懸濁液を12,000×gで5分間遠心分離し、上清を低張液画分1として回収した。細胞を250μLの低張液に懸濁し、12,000×gで5分間遠心分離し、上清を低張液画分2として回収した。細胞を250μLのPBSに懸濁し、超音波破砕機(UH-50:SMT社)で30秒×2回破砕し、12,000×gで5分間遠心分離し、上清を破砕画分1として回収した。細胞を250μLのPBSに懸濁して洗浄した後、12,000×gで5分間遠心分離し、上清を破砕画分2として回収した。
(1)と同様に、250μLの培養液を6,400×gで10分間遠心分離し上清と細胞に分けた。細胞を250μLのTris/EDTA緩衝液(100mM Tris/HCl、10mM EDTA pH7.4)に懸濁し、室温で90分間静置した後、12,000×gで5分間遠心分離し、上清をT/E画分1として回収した。細胞を250μLのTris/EDTA緩衝液に再度懸濁して細胞を洗浄し、12,000×gで5分間遠心分離した。上清をT/E画分2として回収した。細胞を250μLのPBSに懸濁し、超音波破砕機(UH-50:SMT社)で30秒×2回破砕し、12,000×gで5分間遠心分離し、上清を破砕画分1として回収した。細胞を250μLのPBSに懸濁して洗浄した後、12,000×gで5分間遠心分離し、上清を破砕画分2として回収した。
上記のコールドオスモティックショック法およびTris/EDTA法で回収した各画分6μLに2μLの4×Laemmli Sample Buffer(Biorad社)を加えて混合し、95℃で5分間加熱したあと3μLをポリアクリルアミドゲルにアプライした。SDS-PAGE後、PVDF膜にブロッティングし、Blockng One(ナカライテスク社)でブロッキングした。TBS-Tで洗浄後、抗ヒト化VHHポリクローナルウサギ抗体と抗ウサギポリクローナルヤギ抗体-HRPを用いて抗体反応を行い、EzWestLumi plus(ATTO社)を用いて検出し、ChemiDoc(Biorad社)とQuantity One(Biorad社)を用いてバンド強度を求めた。バンド強度から、各画分の回収率を算出した。コールドオスモティックショック法では、高張液画分1、2、低張液画分1、2を合わせたものを、Tris/EDTA法では、T/E画分1、2を合わせたものを回収量とした。破砕画分1、2から生成された分も合わせた、菌体からの全抗vWFナノボディ(目的タンパク質)に占める、前記回収量の割合(回収効率)を算出し、野生株と外膜形成関連遺伝子改変大腸菌株での違いを調べた(表1)。野生株と外膜形成関連遺伝子改変大腸菌株の比較したところ、palやlppが改変された株を用いることで、コールドオスモティックショック法とTris/EDTA法のいずれにおいても回収率が向上した。
本実施例は、大腸菌の一遺伝子欠損ライブラリーであるKeio collectionを用いて、外膜形成関連遺伝子改変大腸菌株からの目的タンパク質の回収効率を調べるために実施した。本実施例では、大腸菌BW25113の変異株であるKeio collectionのompA、tolA、mepS、nlpI、arcA、cyoA、dppA、ecnB、mrcA、mrcB、oppA、及びslyBの欠損株に、目的タンパク質として抗vWFナノボディを産生させ、その回収効率を調べた。各変異株に抗vWFナノボディをコードする遺伝子(配列番号54)を含む発現用ベクターをエレクトロポレーション法によって導入し、0.8 mLの半合成培地で培養した。各変異株について、菌体の可溶性画分に含まれる抗vWFナノボディ(目的タンパク質)の総和を回収率100%として、ペリプラズム画分から回収された目的タンパク質の回収効率を算出した。各画分は、実施例2と同様の条件で、コールドオスモティックショック法により調製した。また、各画分の抗vWFナノボディは、実施例2と同様の条件でウェスタンブロッティング解析を行った。
Claims (11)
- 下記の(a)~(c)の工程を含む、タンパク質の製造方法:
(a)外膜構造の維持に関連する遺伝子が改変された大腸菌に目的の外来タンパク質をコードする遺伝子を導入する工程、
(b)(a)の大腸菌を培養する工程、及び
(c)培養後の菌体のペリプラズム画分より目的の外来タンパク質を回収する工程。 - 前記外膜構造の維持に関連する遺伝子が、pal、lpp、ompA、tolA、mepS、nlpI、arcA、bamD、cyoA、dppA、ecnB、mrcA、mrcB、oppA、及びslyBからなる群から選択される少なくとも1つである、請求項1に記載の方法。
- 前記大腸菌の、pal、lpp、ompA、tolA、mepS、nlpI、arcA、bamD、cyoA、dppA、ecnB、mrcA、mrcB、oppA、及びslyBからなる群から選択される2つ以上の遺伝子が改変されている、請求項1又は2に記載の方法。
- 前記大腸菌の、pal、lpp、ompA及びtolAからなる群から選択される少なくとも1つの遺伝子が改変されている、請求項1又は2に記載の方法。
- 前記改変が完全欠損である、請求項1~4のいずれか1項に記載の方法。
- 前記改変が部分変異である、請求項1~4のいずれか1項に記載の方法。
- 前記改変がシグナル配列の部分変異である請求項6に記載の方法。
- 前記改変が構造遺伝子の部分変異である請求項6に記載の方法。
- 前記大腸菌が、B株由来またはK12株由来である請求項1~8のいずれか1項に記載の方法。
- タンパク質を製造するための宿主大腸菌の作製方法であって、下記の(i)及び(ii)の工程を含む、方法:
(i)大腸菌の外膜構造の維持に関連する遺伝子を改変させる工程;及び
(ii)(i)で得られた遺伝子が改変された大腸菌に、目的の外来タンパク質をコードする遺伝子を導入する工程。 - 前記大腸菌が目的の外来タンパク質を発現し、前記目的の外来タンパク質が前記大腸菌のペリプラズムに蓄積される、請求項10に記載の方法。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22774718.5A EP4317169A1 (en) | 2021-03-22 | 2022-02-07 | Production method for foreign protein using escherichia coli |
JP2023508751A JPWO2022201917A1 (ja) | 2021-03-22 | 2022-02-07 | |
US18/466,984 US20240052393A1 (en) | 2021-03-22 | 2023-09-14 | Method for producing foreign protein using e. coli |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021046808 | 2021-03-22 | ||
JP2021-046808 | 2021-03-22 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/466,984 Continuation US20240052393A1 (en) | 2021-03-22 | 2023-09-14 | Method for producing foreign protein using e. coli |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022201917A1 true WO2022201917A1 (ja) | 2022-09-29 |
Family
ID=83395496
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2022/004680 WO2022201917A1 (ja) | 2021-03-22 | 2022-02-07 | 大腸菌を用いた外来タンパク質の製造方法 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20240052393A1 (ja) |
EP (1) | EP4317169A1 (ja) |
JP (1) | JPWO2022201917A1 (ja) |
WO (1) | WO2022201917A1 (ja) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08242879A (ja) | 1995-01-31 | 1996-09-24 | Sanofi Sa | アルギニンの存在下での原核微生物由来ペリプラズムタンパクの抽出方法 |
WO1998014600A1 (es) | 1996-10-03 | 1998-04-09 | Centro De Ingenieria Genetica Y Biotecnologia (Cigb) | SISTEMA DE TRANSFORMACION EN $i(CANDIDA UTILIS) |
WO2013016428A2 (en) * | 2011-07-25 | 2013-01-31 | Pfizer Inc. | Recombinant apoa-1m from engineered bacteria |
JP2021046808A (ja) | 2019-09-18 | 2021-03-25 | 株式会社オティックス | 動弁装置 |
-
2022
- 2022-02-07 EP EP22774718.5A patent/EP4317169A1/en active Pending
- 2022-02-07 WO PCT/JP2022/004680 patent/WO2022201917A1/ja active Application Filing
- 2022-02-07 JP JP2023508751A patent/JPWO2022201917A1/ja active Pending
-
2023
- 2023-09-14 US US18/466,984 patent/US20240052393A1/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08242879A (ja) | 1995-01-31 | 1996-09-24 | Sanofi Sa | アルギニンの存在下での原核微生物由来ペリプラズムタンパクの抽出方法 |
WO1998014600A1 (es) | 1996-10-03 | 1998-04-09 | Centro De Ingenieria Genetica Y Biotecnologia (Cigb) | SISTEMA DE TRANSFORMACION EN $i(CANDIDA UTILIS) |
WO2013016428A2 (en) * | 2011-07-25 | 2013-01-31 | Pfizer Inc. | Recombinant apoa-1m from engineered bacteria |
JP2021046808A (ja) | 2019-09-18 | 2021-03-25 | 株式会社オティックス | 動弁装置 |
Non-Patent Citations (10)
Title |
---|
"Advances in Applied Biotechnology", 20 January 2012, INTECH, ISBN: 978-953-30-7820-5, article WAEGEMAN HENDRIK, DE MARJAN: "Increasing Recombinant Protein Production in E. coli by an Alternative Method to Reduce Acetate", XP055971207, DOI: 10.5772/30726 * |
C. SCHIMEK ET AL., BIOTECHNOL. PROGRESS, vol. 36, 2020, pages e2999 |
CASCALES ELLOUBES R., MOL. MICROBIOL., vol. 51, no. 3, 2004, pages 873 - 885 |
CURR. GENET., vol. 10, no. 8, 1986, pages 573 - 578 |
DATSENKO K.AWANNER B.L, PROC. NATL. ACAD. SCI., U.S.A, vol. 97, no. 12, 2000, pages 6640 - 6645 |
FEMS MICROBIOLOGY LETTERS, vol. 165, 1998, pages 335 - 340 |
LINK A. J ET AL., J. BACTERIOL., vol. 179, 1997, pages 6228 - 6237 |
OURNAL OF BACTERIOLOGY, December 1995 (1995-12-01), pages 7171 - 7177 |
YANG HAIQUAN; WANG FUXIANG; WANG HAOKUN; LU XIAO; SHEN WEI; CHEN XIANZHONG: "DeletingmrdAandmrcBto significantly improve extracellular recombinant protein production inEscherichia coli", BIOCHEMICAL ENGINEERING JOURNAL, ELSEVIER, AMSTERDAM, NL, vol. 143, 1 January 1900 (1900-01-01), NL , pages 185 - 195, XP085604541, ISSN: 1369-703X, DOI: 10.1016/j.bej.2019.01.003 * |
ZHAO-YUAN CHEN, JIE CAO, LI XIE, XIAO-FEI LI, ZHEN-HAI YU, WANG-YU TONG: "Construction of leaky strains and extracellular production of exogenous proteins in recombinant E scherichia coli : Extracellular production of exogenous proteins", MICROBIAL BIOTECHNOLOGY, WILEY-BLACKWELL PUBLISHING LTD., GB, vol. 7, no. 4, 1 July 2014 (2014-07-01), GB , pages 360 - 370, XP055561732, ISSN: 1751-7915, DOI: 10.1111/1751-7915.12127 * |
Also Published As
Publication number | Publication date |
---|---|
JPWO2022201917A1 (ja) | 2022-09-29 |
EP4317169A1 (en) | 2024-02-07 |
US20240052393A1 (en) | 2024-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6636661B2 (ja) | 大腸菌における組換えcrm197の産生強化 | |
Qian et al. | Proteome‐based identification of fusion partner for high‐level extracellular production of recombinant proteins in Escherichia coli | |
US10287330B2 (en) | Methods and compositions relating to CRM197 | |
Kanemori et al. | The ATP-dependent HslVU/ClpQY protease participates in turnover of cell division inhibitor SulA in Escherichia coli | |
JPH07502647A (ja) | ユビキチン特異的プロテアーゼ | |
JPH06500006A (ja) | ユビキチン特異的プロテアーゼ | |
KR101739128B1 (ko) | 재조합 crm197의 고 수준 발현 | |
Li et al. | High-efficiency expression and secretion of human FGF21 in Bacillus subtilis by intercalation of a mini-cistron cassette and combinatorial optimization of cell regulatory components | |
Sun et al. | Enhanced production of recombinant proteins in Corynebacterium glutamicum by constructing a bicistronic gene expression system | |
US20080233614A1 (en) | Production of recombinant collagenases colg and colh in escherichia coli | |
JP2012508001A (ja) | 機能グループii莢膜遺伝子クラスターを有しないe.colibl21株 | |
JP2004507270A (ja) | 組換えヒト副甲状腺ホルモンを生産する形質転換酵母及び該ホルモンの生産方法 | |
WO2022201917A1 (ja) | 大腸菌を用いた外来タンパク質の製造方法 | |
JP2020533980A (ja) | 組換えタンパク質の分泌を増加させる方法 | |
JP7233203B2 (ja) | M23aファミリープロテアーゼの製造方法 | |
WO2021200784A1 (ja) | 大腸菌を用いた外来タンパク質の製造方法 | |
US20220064227A1 (en) | Recombinant strains and medium formulation for enhancing secretion titer using a type iii secretion system | |
WO2023286629A1 (ja) | 大腸菌を用いたプラスミドdnaの製造方法 | |
JPH10150984A (ja) | 抗体分子の製造方法 | |
KR20240053728A (ko) | 세포외막 지질단백질 PrsA 발현계를 이용한 세포표면 대량발현 기술 | |
Tan et al. | The role of lac operon and lac repressor in the induction using lactose for the expression of periplasmic human | |
JP4696915B2 (ja) | タンパク質の分泌産生システム | |
Zainol et al. | Overexpression, extraction, purification and characterisation of DppA from Escherichia coli | |
KR20050085190A (ko) | 저온-유도성 발현 벡터 | |
JPH09313191A (ja) | 蛋白質の分泌生産法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22774718 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2023508751 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022774718 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022774718 Country of ref document: EP Effective date: 20231023 |